STOCK TITAN

Zealand Pharma major shareholder announcement: Van Herk Investments

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Zealand Pharma (Nasdaq: ZEAL) has announced a significant shareholder update on October 10, 2022. Van Herk Investments B.V. now holds 7,630,244 shares, representing 14.81% of Zealand’s total share capital and voting rights as of October 7, 2022. The announcement details the ownership structure, indicating that Van Herk Investments is ultimately controlled by Mr. Adrianus van Herk. Zealand Pharma continues to focus on developing peptide-based medicines, with multiple drug candidates in clinical development.

Positive
  • Van Herk Investments holds a significant 14.81% of Zealand's total share capital, potentially stabilizing shareholder support.
  • Zealand Pharma has over 10 drug candidates in clinical development, demonstrating a robust pipeline.
Negative
  • None.

Company announcement – No. 46 / 2022

Zealand Pharma major shareholder announcement: Van Herk Investments

Copenhagen, Denmark and Boston, MA, 10 October 2022Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification dated 10 October 2022 pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

As from 7 October 2022 Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,630,244 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 14,81% of the total share capital and total voting rights Zealand Pharma A/S.

Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V. which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543, which is ultimately owned and controlled by Mr. Adrianus van Herk.

Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,630,244 shares (each share carrying one vote), corresponding to 14,81% of the total share capital and total voting rights in Zealand Pharma A/S.

Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk.

Please see further details in the attached notification forms.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contact:

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com

 

David Rosen (U.S. Media)
Argot Partners
Email: media@zealandpharma.com
        

 

Attachments


FAQ

What is the latest shareholder announcement from Zealand Pharma?

On October 10, 2022, Zealand Pharma announced that Van Herk Investments B.V. holds 14.81% of its shares.

Who controls Van Herk Investments B.V.?

Van Herk Investments B.V. is ultimately controlled by Mr. Adrianus van Herk.

How many shares does Van Herk Investments hold in Zealand Pharma?

Van Herk Investments holds 7,630,244 shares in Zealand Pharma.

What percentage of Zealand Pharma's voting rights does Van Herk Investments control?

Van Herk Investments controls 14.81% of Zealand Pharma's total voting rights.

What is Zealand Pharma's focus in biotechnology?

Zealand Pharma focuses on the discovery and development of innovative peptide-based medicines.

ZEAL

NASDAQ:ZEAL

ZEAL Rankings

ZEAL Latest News

ZEAL Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Denmark
Sydmarken 11